1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Babylon Holdings Limited

Babylon Holdings Limited

BBLNF
Babylon Holdings LimitedUS flagOther OTC
0.00
USD
- -
- -
2,561.00Market Cap
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
0.17
0.85
3.45
60.18
58.99
Basic EPS, GAAP
-1.51
-2.28
-0.83
-12.01
-9.88
Free Cash Flow per Basic Share
-1.55
-1.94
-2.04
-16.89
-13.86
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
-3.04
-5.06
-6.62
-45.38
-45.99
Tangible Book Value per Share
1.4
-0.52
-2.77
-13.88
-16.1
Basic Weighted Avg Shares
93
93
93
18
20
Sales/Revenue/Turnover
16
79
321
1,110
1,154
Operating Margin (%)
-1,015.47
-246.46
-82.97
-30.37
-25.88
Depreciation Expense
2
4
9
12
10
Net Income, GAAP
-140
-212
-77
-221
-193
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
-874.93
-267.18
-24.13
-19.96
-16.75
Working Capital
191
6
149
58
12
LT Debt
4
2
177
292
308
Total Equity
174
48
-161
-256
-315
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
ST Debt
5
5
5
LT Borrowings
270
278
295
LT Finance Leases
16
14
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
94
25
26
Market Capitalization
416
119
100

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
Total Current Assets
160
220
183
Cash, Cash Equivalents & STI
110
43
26
Accounts Receivable, Net
30
16
15
Inventories
- -
- -
- -
Total Current Liabilities
145
162
172
Payables & Accruals
119
57
63
ST Debt
5
5
5
Deferred Revenue
20
19
19

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
58.58%
Free Cash Flow
- -
- -
64.38%
Net Income, GAAP
- -
- -
186.08%
Sales/Revenue/Turnover
- -
- -
245.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
71
57
74
120
321
2022
266
265
289
289
1,110
2023
311
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.11
-0.69
-0.7
-2.46
-0.83
2022
-1.71
-10.2
-5.75
5.26
-12.01
2023
-2.53
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Aron England
Full Time Employees
1,895
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Address
2500 Bee Cave Road London United Kingdom
IPO Date
Oct 25, 2021
CIK
0001866390
Website
babylonhealth.com
Similar Companies
MSP Recovery, Inc. (LIFWZ)
Aladdin Healthcare Technologies SE (ALDNF)
FOXO Technologies Inc. (FOXO)
Spok Holdings, Inc. (SPOK)
Hinge Health, Inc. (HNGE)
SHL Telemedicine Ltd. (SHLTN.SW)
Business
Babylon Holdings Limited operates as a digital healthcare company that provides end-to-end primary care solutions through its digital health suite, virtual consultations, in-person medical care, post-care support, Babylon Cloud platform, and clinical services; offerings include AI-driven symptom checkers, telemedicine GP appointments, mental health support, physiotherapy, weight management programs, and pharmacy services targeting consumers, employers, governments, and health systems primarily in the United Kingdom, United States, Canada, Rwanda, and other international markets. Founded in 2013 and headquartered in Austin, Texas, with key operations based in London, United Kingdom, the company maintains subsidiaries such as Babylon Partners Ltd for product development and previously encompassed pharmacy, backward linkage, agribusiness, technology, and logistics segments before refocusing on core health services. In recent major changes, Babylon Holdings filed for Chapter 7 bankruptcy liquidation in August 2023 for its U.S. subsidiaries amid a failed merger with MindMaze and AlbaCore Capital, sold substantially all UK assets including Babylon Healthcare Services Ltd to eMed Healthcare UK in late 2023 to ensure service continuity and expand into remote chronic care like semaglutide-based weight management, closed U.S. operations with layoffs, and now powers limited UK offerings such as GP at Hand, SheMed, HeMed, and obesity screening kits through eMed integration as of 2025.